Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

ABSTRACT Aims/Introduction PIONEER REAL Japan was a non‐interventional prospective
study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice …

Obesity is a complex health issue with growing prevalence worldwide. It is also becoming
more prevalent in the population of older adults (ie, 65 years of age and older), affecting …

Aims To understand glucagon-like peptide-1 receptor agonist (GLP-1RA) use in patients
with type 2 diabetes (T2D) in Japan. Methods Characteristics of people receiving GLP-1RAs …

Abstract Glucagon-Like Peptide 1 receptor agonist (GLP-1RA) have been recently effective
for diabetes. Among them, subcutaneous injection and oral form of semaglutide (Rybelsus) …

Aims To investigate the impact of baseline characteristics on the efficacy of once‐weekly
subcutaneous semaglutide 0.5 and 1.0 mg in participants with type 2 diabetes (T2D) from …

Background Oral semaglutide in older subjects with type 2 diabetes was as effective as in
younger subjects, according to phase 3 clinical trials. However, its efficacy can be limited in …

This systematic review aimed to compare the influence of glucagon-like peptide-1 receptor
agonists (GLP-1RAs) on the efficacy and safety of elderly patients with type 2 diabetes and …

As recommended pharmacological agents for type 2 diabetes mellitus (T2DM), Glucagon-
Like Peptide 1 receptor agonist (GLP-1Ra) is highly evaluated for its various beneficial …

Background Dipeptidyl peptidase-4 inhibitors (DPP-4is) are the most widely used oral
hypoglycemic drugs in Japan. However, once-daily oral semaglutide has been reported to …